A5080682696- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Nonmelanoma Skin Cancer Studies
- Ocular Oncology and Treatments
- Immunotherapy and Immune Responses
- Cutaneous lymphoproliferative disorders research
- TGF-β signaling in diseases
- Cancer and Skin Lesions
- Esophageal Cancer Research and Treatment
- Cancer Genomics and Diagnostics
- Management and Marketing Education
- Myasthenia Gravis and Thymoma
- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Molecular Biology Techniques and Applications
- Retinal Development and Disorders
- Kruppel-like factors research
- Reproductive Biology and Fertility
- Metabolism, Diabetes, and Cancer
- Risk and Safety Analysis
- Lymphoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Human-Automation Interaction and Safety
- Media, Gender, and Advertising
Bioscience (China)
2021
University of Pennsylvania
2020
Cleveland State University
1979-2015
Ohio University
1983-2015
West Virginia University
1991-2015
Chestnut Hill College
2014
Baylor College of Medicine
2010-2012
St. Joseph's Hospital and Medical Center
2012
The University of Queensland
2011
Northwestern University
1970-2010
Abstract Purpose: The development of a genetic signature for the identification high-risk cutaneous melanoma tumors would provide valuable prognostic tool with value stage I and II patients who represent remarkably heterogeneous group 3% to 55% chance disease progression death 5 years from diagnosis. Experimental Design: A 28-gene was identified by analysis microarray expression data. Primary tumor tissue evaluated RT-PCR signature, radial basis machine (RBM) modeling performed predict risk...
The heterogeneous behavior of patients with melanoma makes prognostication challenging. To address this, a gene expression profile (GEP) test to predict metastatic risk was previously developed. This study evaluates the GEP's prognostic accuracy in an independent cohort cutaneous patients. multi-center analyzed primary tumors from 523 patients, using GEP classify as Class 1 (low risk) and 2 (high risk). Molecular classification correlated clinical outcome assessed along AJCC v7 staging...
A substantial number of patients who relapse and die from cutaneous melanoma (CM) are categorized as being at low risk by traditional staging factors. The 31-gene expression profile (31-GEP) test independently stratifies metastatic with CM (Class 1, 1A indicating lowest risk) or high 2,with 2B highest risk).To assess prediction the 31-GEP within 3 low-risk (according to American Joint Committee on Cancer) populations CM: those sentinel lymph node (SLN) negative, stage I IIA tumors, thin (≤1...
Current staging systems for cutaneous squamous cell carcinoma (cSCC) have limited positive predictive value identifying patients who will experience metastasis.To develop and validate a gene expression profile (GEP) test predicting risk metastasis in localized, high-risk cSCC with the goal of improving risk-directed patient management.Archival formalin-fixed paraffin-embedded primary tissue clinicopathologic data (n = 586) were collected from 23 independent centers prospectively designed...
In designing a self-checking processor, it is essential to recognize the types of failures that are most probable. Matching checking techniques with type faults expected occur should yield best result least amount hardware. The microprogram control will consist integrated circuits: large-scale integration (LSI) for memory and small-scale (SSI) associated logic. Because density chips on plug-in package physical proximity devices an circuit, multiple within single circuit highly have been...
A 31-gene expression profile (GEP) test that provides risk classification of cutaneous melanoma (CM) patients has been validated in several retrospective studies. The objective the reported study was a prospective evaluation GEP performance enrolled two clinical registries. Three-hundred twenty CM EXPAND (NCT02355587) and INTEGRATE (NCT02355574) registries met criteria age ≥ 16 years, successful result ≥1 follow-up visit for inclusion this interim analysis. Primary endpoints were...
Can gene expression profiling be used to identify patients with T1-T2 melanoma at low risk for sentinel lymph node (SLN) positivity?Bioinformatics modeling determined a population in which 31-gene profile test predicted <5% SLN positivity. Multicenter, prospectively-tested (n = 1421) and retrospective 690) cohorts were validation outcomes, respectively.Patients 55-64 years ≥65 class 1A (low-risk) had positivity rates of 4.9% 1.6%. Class 2B (high-risk) 30.8% 11.9%. Melanoma-specific survival...
Objective: DecisionDx-Melanoma* is a 31-gene expression profile test that predicts the risk of metastasis in patients with primary cutaneous melanoma (CM). This study was designed to ascertain clinical management changes determined by outcome, which classifies CM being at low (Class 1) or high 2) for recurrence.Research design and methods: Medical charts were reviewed from 156 six institutions (three dermatology three surgical oncology practices) who consecutively tested between May 2013...
National guidelines recommend sentinel lymph node biopsy (SLNB) be offered to patients with > 10% likelihood of (SLN) positivity. On the other hand, do not SLNB for T1a tumors without high-risk features who have < 5% a positive SLN. However, decision perform is less certain higher-risk T1 melanomas in which expected 5%-10% time. We hypothesized that integrating clinicopathologic 31-gene expression profile (31-GEP) score using advanced artificial intelligence techniques would provide more...
Journal Article THE NEW INDUSTRIAL REVOLUTION: Amazing Increases in Productivity of Labor--Due Large Part to Immigration Restriction--Eugenic Significance Such Changes Get access Robert Cook Search for other works by this author on: Oxford Academic PubMed Google Scholar Heredity, Volume 18, Issue 1, January 1927, Pages 19–21, https://doi.org/10.1093/oxfordjournals.jhered.a102752 Published: 01 1927
PURPOSE The DecisionDx-Melanoma 31-gene expression profile (31-GEP) test is validated to classify cutaneous malignant melanoma (CM) patient risk of recurrence, metastasis, or death as low (class 1A), intermediate 1B/2A), high 2B). This study aimed examine the effect 31-GEP testing on survival outcomes and confirm prognostic ability at population level. METHODS Patients with stage I-III CM a clinical result between 2016 2018 were linked data from 17 SEER registries (n = 4,687) following...
Dynamic microprogramnming (i. e., utilizing a READ/ WRITE microstorage) allows the structure of computer to be altered suit problem at hand and results in major efficiencies (an order magnitude) running time for nonarithmetic programs (e. g., compilers).
A significant proportion of patients with American Joint Committee on Cancer (AJCC)-defined early-stage cutaneous melanoma have disease recurrence and die. 31-gene expression profile (GEP) that accurately assesses metastatic risk associated primary melanomas has been described.We sought to compare accuracy the GEP in combination determined using web-based AJCC Individualized Melanoma Patient Outcome Prediction Tool.GEP results from 205 stage I/II sufficient clinical data for prognostication...
Uveal melanoma management is challenging due to its metastatic propensity. DecisionDx-UM a prospectively validated molecular test that interrogates primary tumor biology provide objective information about potential can be used in determining appropriate patient care. To evaluate the continued clinical validity and utility of DecisionDx-UM, beginning March 2010, 70 patients were enrolled prospective, multicenter, IRB-approved study document differences outcomes associated with low-risk Class...
Current guidelines for postoperative management of patients with stage I-IIA cutaneous melanoma (CM) do not recommend routine cross-sectional imaging, yet many these develop metastases. Methods that complement American Joint Committee on Cancer (AJCC) staging are needed to improve identification and treatment patients. A 31-gene expression profile (31-GEP) test predicts metastatic risk as low (class 1) or high 2). Prospective analysis CM outcomes was performed the hypotheses 31-GEP provides...
The DecisionDx-Melanoma test provides prognostic information for patients with cutaneous melanoma (CM). Using formalin-fixed paraffin-embedded primary tumor tissue, the RT-PCR-based classifies into a low- (Class 1) or high-risk 2) category recurrence based on expression of 31 genes. current study was designed to assess analytical validity this test.Inter-assay, inter-instrument, and inter-operator studies were performed evaluate reliability 31-gene results, sample stability reagent...
Assess current clinical practices for uveal melanoma (UM) and the impact of molecular prognostic testing on treatment decisions.Cross-sectional survey sequential medical records review.Ophthalmologists who treat UM.(A) Medical review all Medicare beneficiaries tested by UM gene expression profile in 2012, conducted under an institutional board-approved protocol. (B) 109 ophthalmologists specializing were invited to participate 24-question 2012; 72 a 23-question 2014.Responses analyzed...